Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
Investment will fund expansion to meet rising demand for CRDMO services
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Q2 FY25 Total Income was at Rs. 85.4 crore
Aragen Life Sciences is the first Indian CRDMO to receive SBTi approval
Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
The partnership will focus on creating capabilities for quickly and accurately processing vast amounts of clinical data
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
Subscribe To Our Newsletter & Stay Updated
